Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P41247
UPID:
PLPL4_HUMAN
Alternative names:
Calcium-independent phospholipase A2-eta; Protein GS2
Alternative UPACC:
P41247; A8K1H3; B4E362; Q8WW83
Background:
Patatin-like phospholipase domain-containing protein 4, also known as Calcium-independent phospholipase A2-eta and Protein GS2, is encoded by the gene symbol P41247. It exhibits significant triacylglycerol lipase activity, crucial for transferring fatty acids from triglyceride to retinol, hydrolyzing retinylesters, and generating 1,3-diacylglycerol from triglycerides. This protein also demonstrates acylglycerol transacylase and phospholipase A2 activities, playing a pivotal role in lipid metabolism.
Therapeutic significance:
Understanding the role of Patatin-like phospholipase domain-containing protein 4 could open doors to potential therapeutic strategies.